Good day, welcome to the first quarter 2018 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Tim Lange. Please go ahead, sir.
Yeah, thank you very much, good morning, ladies and gentlemen, welcome to our Q1 earnings conference call. My name is Tim Lange, Head of Investor Relations, and with me today is Ute Wolf, CFO of Evonik. With that, I'll hand directly over to Ute for our short presentation, followed, as usual, by the Q&A session.
Thank you, Tim, also a warm welcome from me. Thanks for taking the time to be with us today. Our first quarter results stand for steady progress on our agenda for 2018. Strategy execution and earnings growth are and will remain key for us. In the execution of our strategy, the announced divestment of our methacrylate business is an important step forward. The divestment process is well on track. The same applies to our SG&A efficiency program. We are working out the details and will give the next update by end of June. Another element in our move to build a more balanced and more focused specialty portfolio is the investment into our new polyamide 12 plant. This project strengthens our growth engine, Smart Materials, in market segments with resilient growth and profitability.
With these high-performance polymers, we are serving fast-growing market trends like 3D printing, biocompatible heart catheters, or highly flexible sheathing for optical cables. Our four growth engines are essential building blocks of our specialty portfolio, serving highly attractive markets with above-average growth rates. Recent market developments prove that we are building on and benefiting from the right needs. Just to give you some examples. Besides PA 12, silica for the famous green tire is another growth driver in Smart Materials. Here we are now also serving fuel-saving large SUV and all-season tires. With our Specialty Additives, we deliver performance-enhancing solutions for energy efficient housing. In our growth engine Animal Nutrition, we are strengthening our leading role in the field of sustainable and antibiotic-free livestock management. Our drug delivery technologies in Health and Care turns drugs into high-performance medicines to heal severe diseases or to prevent addiction.
Overall, our growth engines will guarantee GDP plus growth rates across our specialties portfolio. Let's take a look into the numbers on slide five. We had a good start to the year with earnings well above the prior year quarter. This is a quite remarkable achievement as we faced notable headwinds from FX and raw materials. Given the headwinds, we are pleased that our EBITDA margin of 18.5% is within our target range of 18%-20%. Apart from the unchanged healthy trends in our markets, support from synergies and the first benefits from cost savings are becoming more and visible. Volumes are positive in the quarter. The 1% increase is below our ambition. The modest rise is explained twofold. Firstly, by the strong prior year level, when volumes grew 8% for the group, driven by restocking at the start of 2017.
Secondly, by planned maintenance shutdowns in Resource Efficiency impacted volumes on group levels by more than one percentage point. Let's take a closer look into our earnings development. For the first time since the third quarter of 2015, we have seen earnings growth in all three segments. This is remarkable, as earnings growth overcompensated the pretty pronounced impact from a weaker U.S. dollar and headwind from higher raw materials. EBITDA margins in all segments improved significantly year-on-year. Ongoing healthy underlying trends in most of our businesses supported this development. Additionally, the positive contribution from synergies and the first benefits from our initiated cost savings in SG&A and operational businesses are becoming visible. Ladies and gentlemen, let's now move to cash flow on slide eight. Good progress is also visible on the free cash flow.
Our free cash flow of EUR 84 million is above the prior year quarter. Cash out for CapEx is lower than in the first quarter of last year, in line with our full-year guidance and another proof of our CapEx discipline. Operating cash flow is exactly on prior year level. Not unusual for the first quarter, we have seen a quite significant cash outflow for net working capital. The rest of the year should provide some relief in this matter. From a full year perspective, the cash outflow from net working capital should be less pronounced than in Q1. Additionally, we had a shift of cash outs for bonus payments. They usually and still predominantly occur in the second quarter. This year, we already had some part of that, around EUR 40 million, in the first quarter.
On a like-for-like basis, the operating cash flow and the free cash flow would have been another EUR 40 million higher in the first quarter. To bring it to the point, free cash flow generation in the first quarter was promising and remains on the top of our priority list. We are fully committed to grow our free cash flow in 2018 and beyond. Let me now give you some more details on the individual segments, starting with Resource Efficiency. Thanks to the successful management of raw material prices and the contribution of Huber Silica, Resource Efficiency was able to offset the impact from FX and lower volumes in Q1. Volumes were, as mentioned, negatively affected by scheduled plant shutdowns in Active Oxygens and Coating & Adhesive Resins. Most of the other businesses delivered a solid performance in Q1.
For example, Coating Additives benefited from our strong position in waterborne low VOC coating formulations, as awareness for more environmentally friendly coating systems is increasing, especially in China. Capacities in Silica and High Performance Polymers are running at high utilization rates to meet the ongoing strong customer demand. Looking into Q2, we are confident of delivering a sequential earnings increase in this segment. Nutrition & Care showed a pleasing and improving operational performance. Virtually all underlying businesses have grown earnings year-on-year. We are particularly pleased by the ongoing successful performance at our growth engine, Health and Care. Healthcare continued its strong growth, which is based on the expanded portfolio of solutions for advanced drug formulations and medical devices. In Personal Care, we have seen growing business and margin expansion in Q1, due to our active ingredients and especially the acquired preservatives business from Dr. Straetmans.
In Animal Nutrition, volumes in Q1 were on a good level, supported by healthy market growth and demand pickup after the Chinese New Year. Our average price was, as expected and guided, stable in local currency. For Q2, we expect sequentially stable earnings for this segment. Concluding with Performance Materials, the segment delivered another strong quarter, mostly driven by methacrylates, where the market environment remains strong. Margins in Q1 continued on attractive levels and in some regions and products even saw a sequential uptick. With tight markets in methacrylates to persist and a slight sequential improvement in the C4 business, we expect Performance Materials to report another strong second quarter. On the back of this good start into the year, we are confirming our full-year outlook, despite more adverse FX effects for 2018.
In the light of the weaker U.S. dollar in the first months of the year, we have changed our assumption for the full year from $1.2 to now $1.26 per euro. Keeping in mind our earnings sensitivity to the dollar, that means that we are compensating for an additional EUR 50 million headwind in 2018. We remain committed to our agenda of consistent strategy execution and earnings growth. For the second quarter specifically, we expect an adjusted EBITDA on the good level of the first quarter. That closes our presentation. Thank you for your attention so far, and we are now happy to discuss your questions.
Thank you. If you would like to ask a question, please signal by pressing star one on your telephone keypad. If you are using a speakerphone, please make sure your mute function is turned off to allow your signal to reach our equipment. Again, press star one to ask a question. We'll pause for just a moment to allow everyone an opportunity to signal. We shall take our first question from Michael Schäfer of Commerzbank. Please go ahead.
Yeah, thanks for taking my question. Two question from my side. First one is on EBITDA growth you have shown in the first quarter. You mentioned that synergies and cost savings are contributing to this one. I wonder whether you can quantify the impact from synergies and the initial part of the cost savings program. That would be my first question. The second is on your cash flow outlook now into the second quarter. You mentioned the advanced bonus payment, but also the working capital expansion ahead of the planned standstills now for the second quarter. Typically, the second quarter is the weakest when it comes to free cash flow. I wonder whether this pattern may change in 2018 given, let's say, the reversal of those facts are just looking as a drag in the first quarter. Any color would be helpful. Thank you.
Yeah, Michael, good morning. Thank you very much for your questions. The structural effects in EBITDA growth are EUR 50 million from SG&A, EUR 15 million in improvement in Baby Care from the dissolution of the joint venture for acrylic acids. We have some first benefits of the Adjust 2020 program in Animal Nutrition, around EUR 10 million for this year. If you take these all together, these are EUR 75 million in this year, which more or less are evenly spread over the quarters. Synergies are another EUR 25 million in 2018. They are a little bit more skewed toward Q2 and Q3, we have not a pro rata distribution for the synergies. Cash flow, the networking capital build up in the first quarter was relatively high as we had these planned shutdowns, especially inventories went up.
If we look to Q2, of course, the inventories built up for the shutdowns will step by step reduce. The overall bonus sum does not change, we have just some push from Q2 to Q1. That's more a timing effect. From that point of view, Q2 is a quarter where you have the bonus payments, the biggest part of the bonus payments and, of course, the dividend, but that's then not relevant for the free cash flow. From that point of view, this general pattern will not change. As I said, we are working very consistently on this issue. I think Q1 has shown the right results here, and we will do the same for Q2, although of course, there are some payouts which are there. For the full year, that's what you also asked.
For the full year, I think that does not change so much the needle. We just made a good step into the right direction. Keep in mind that our cash flow outlook is true for the whole EBITDA range. As we keep the outlook stable, I think we also keep the cash flow outlook for this time stable.
Thank you. Our next question is from Paul Walsh of Morgan Stanley. Please go ahead.
Morning, Ute. Thanks very much for taking my questions. I wonder if you could just give us an update on where we are on the methacrylates disposal, whatever you can say on that front. Secondly, just in terms of the guidance for the second quarter, you talk about Q2 on a level with Q1, I guess if you add up the divisionals, you're expecting a sequential improvement maybe more modest seasonally than we've seen before. Again, any comments around that would be helpful. Thank you.
Paul. Good morning. Thank you for the question. On methacrylates, the project is on track, the usual M&A work streams have, of course, kicked off. The investment bank has been mandated. You surely have seen that. We are preparing for a structured sales process. I think especially important is to structure the new co, as we call it, in a way that we have an attractive Verbund structure and a good product portfolio for the potential buyers. It is a large business. 18 sites are affected, it is complex really to carve out that business, it will take the usual time. Let's stick to the usual procedure you have seen in other cases, how long this may take. We still need one or the other month to go until we can come back with more detail. Guidance for 2. You're right.
If you add the single indications, if you add them up, maybe you get to more than just the good level of Q1. Please keep in mind, if we look at Nutrition & Care, they already had strong volumes in methionine after Chinese New Year. We have to see if there was some pre-buying or not now for the second quarter, because normally there is a volume pickup Q2 versus Q1, we have to see how pronounced that will be this year. The remaining business should continue on strong levels. On the other side, Nutrition & Care is the segment with the most pronounced FX headwinds, the FX effect is significantly higher in Nutrition & Care if you compare it to the other two segments.
With regards efficiency, I think we described that all the businesses should continue on the good levels, show some growth as we know it from the segment. For PM, I think we can have some confidence on the methacrylates business that is running at very good levels. We expect also some, or there might be some improvements in the butadiene spread, that still has to be confirmed here in the next weeks and months. From that point of view, there is also some support and some maybe tailwind for PM. On the other side, in services, we expect a somewhat lower earnings in Q2 than in Q1, more seasonal effect with waste and energy utilities business. If you take that all together, I think you can really make up your own calculation.
Thank you. Our next question is from Gunther Zechmann of Bernstein. Please go ahead.
Hi, good morning, Ute. Good morning, Tim. Thanks for taking my questions. You left your full year EBITDA guidance unchanged, but you had quite a strong start to the year. Can you help us understand what brings you to the high and lower end of that guidance range? As a bolt-on question, you mentioned adverse FX effects earlier. You now assume a dollar-euro level, or euro-dollar level, I should say, of 1.26, which we haven't seen since 2014. What's driving that, please?
Yeah, the dollar has not been so far away from that level just a few weeks ago. I think we merely have seen that this year already. If you look at the consensus for the dollar, it ranges from 1.15 to 1.4, I think our 1.26 is more or less the median and the middle of this. If we look at the full year guidance, I think not much has changed fundamentally. We see a slight increase in EBITDA in Nutrition & Care driven by the normalization in methionine combined with good volume growth, the underlying growth in the other businesses, which I think perform quite well. Baby Care will stay at low levels, that's more or less the same view on this segment, like by the end of this year.
Resource Efficiency, as we said, good volume growth, good earnings growth expected, no change here as well. Performance Materials. We have now 1 good quarter in with acrylics in our pockets. The 2nd looks good. We still don't know how the second half of the year will go. There are assumptions that it might stay so tight, but there are also other views. From that point of view, to look at PM and see that it might maybe not reach the good levels of 2017, I think is still a reasonable approach. Yeah.
That's very helpful. Thank you. Yeah.
The weaker dollar, I think, the guidance is now somewhat tougher in comparison to some months ago.
Thank you.
Our next question is from Thomas Wrigglesworth of Citibank.
Good morning, Ute. Good morning, Tim. A couple of questions, if I may. The first on Resource Efficiency. Just for point of clarification, did you say more than 1% volume growth in Resource Efficiency if we take out the shutdowns in Active Oxygens and Coating & Adhesive Resins? Secondly, on Resource Efficiency, if I took out the other effects, i.e., the Huber acquisition, what would've been the margin development in the quarter? Thirdly, on Performance Materials, the 8% price increase that we see, is that all from MMA coming through there? Or are there offsetting positives and negatives or it's not all MMA in the price effect for Performance Materials? Thank you.
Hey, Thomas. Thank you for the question. The one percentage point is on group level. The effect on the volumes is on group level. For Resource Efficiency, that translates into something like 3%-4%.
Second question was on Huber.
Huber, the margin. I think Huber has more or less comparable margin to the overall Resource Efficiency segment. I don't see so much uptick from there for the segment. For the volume, the price development and Performance Materials, I think if you compare Q1 2017 to 2018, of course, in C4, the price development is negative as we had outstanding price levels in Q1 of 2017. For the overall segment, MMA is the main driver. On the other side, there are also some price effects on the smaller business lines, but that's only marginal.
Could I just ask, could you quantify that C4 negative from the butadiene price? Is that possible?
As we do not really discuss effect on single product level, I can only give you maybe the overall data. Last year, we had a butadiene-to-acrylonitrile spread of EUR 1,000, and this year it was around EUR 350, EUR 400. Maybe that gives you a little bit of an idea what the change might be.
Excellent. That's very helpful. Thank you very much.
Our next question is from Martin Roediger of Kepler Cheuvreux. Go ahead.
Good morning. Thanks for taking my questions. First on the utilization rate. You mentioned several times in the quarter report that utilization rates are quite high, especially in High Performance Polymers, in silica, obviously in healthcare, as well as in MMA and PMMA. Do you see limitations for volume growth going forward? The second question is again on the shutdowns in Active Oxygens and Coating & Adhesive Resins, which might have resulted into an absence of sales by round about EUR 50 million when I put all these bits and pieces together. Can you quantify the related earnings effect in Resource Efficiency from these shutdowns? Do you see any other maintenance shutdowns to come in the rest of the year having any meaningful impact on earnings? The final question is on crosslinkers. You mentioned the high demand in IPDI products, so the isophorone chain.
I know that raw materials are, for example, isocyanates. How successful have you been to pass on higher raw material costs to the customers, or is there any time lag, and thus we should expect some further price effects in crosslinkers to come? Thanks.
Okay, Martin, thank you for your questions. The high utilization, I think for MMA, that clearly represents a restriction on volumes as we do not invest into growth here. For the other business, silica, we have a new facility which will open this year in the U.S. For PA 12, we are planning a new facility, and we have opened up another facility last year for the 3D printing. I think we're well on track here. Maybe to give you some idea for the growth segments, of course, we have a long-term capacity planning, which underpins our volume growth ambition. I think that's pretty well on track. For MMA, I think that's what you see in the market. Demand growth with limited supply growth, that's where we are there. The earnings effect from the planned shutdowns, it's relatively small.
It's like some 10 million or so. We have maintenance shutdowns throughout the year. I think it does not really help so much if we discuss single shutdowns in one quarter or the other, as we have this over the year. It is fully included in our guidance. I think nothing really which we need to take a look at specifically. Crosslinkers, normally we pass on raw material prices with a certain time lag. Sometimes we manage to really do the price increases relatively early when we see the raw material price increase coming. From that point of view, Crosslinkers is absolutely positioned in a way that they can pass on the prices. Normally, you have between one and three months time lag. It depends a little bit on the product, on the market, on the overall situation, but that's what we normally see there.
Thank you very much.
Our next question is from Thomas Svoboda of Societe Generale. Please go ahead.
Yes. Good morning. Thank you for taking two questions. Both are follow-ups. The first on the input cost increases on a more general basis, I think it's mostly relevant to Resource Efficiency. Were you able to pass through the input cost increases during the quarter, or is there a general lag effect not only for single businesses but for the segment? That's the first question. The second question, if I may risk, again, on the free cash flow guidance, would you like to comment on how comfortable do you feel with the consensus expectation on free cash flow generation? I think it stands at +25% year-over-year. The guidance you have given with the full-year numbers is a slight increase. Any comment you could make here would be very helpful. Thank you.
Great. I think generally, we were able to pass on the raw material cost increase. If you have a look how really the raw material prices were upwards slightly across all segments. If you look at Nutrition & Care, it is some 2%, Resource Efficiency 1%, PM 3%. It is not these big jumps, so normally in our business, that is taken into account in the pricing a little bit in advance whenever possible. It is not always possible, but if and when they do it. On the free cash flow, I think we have given you the indication on some 10% increase on previous level. That more or less leads already to the consensus, so I think the difference is not so big. We said it holds true for the whole range.
That means, of course, if we should end up in the higher part, free cash flow is of course higher. If we should add up in the lower range, we have to work harder. This is still how we see it.
This is helpful. Thank you very much.
Our next question is from Andreas Heine of MainFirst. Please go ahead.
Yes, thanks for taking my question. I'd like to start with Resource Efficiency and the guidance for Q2. If I look back to the recent years, I realize that it is the seasonal pattern, basically, that the second quarter is stronger than Q1. Is that what you're referring to, or are there other trends which might lead to a more pronounced than the usual seasonal pattern from Q1 to Q2 for this segment? Second, in MMA, as far as I can see, the price trends for MMA during the first quarter, it was consistently going up. That means you go out of the first quarter at a higher level than the average price was. Doesn't that mean that MMA shouldn't be quite a step up again in the second quarter, or do you see any different from your incoming orders?
Last but not least, could you update us on the total portfolio, what you expect to sell with the MMA business at the sales side? You said that that has still to be fixed. Is there something where you made progress and can be more explicit in what will really be for sale? Thank you.
Andreas. Thank you for the question. First, to Resource Efficiency in Q2, please keep in mind they have FX headwinds, that maybe they might even be more pronounced in Q2 than in Q1, depending where especially the dollar goes. From that point of view, I would expect a normal growth rate here. Nothing specific from cyclicality in this respect. MMA prices, yes, we have seen good pricing levels. We all know that this has some structural reasons as new capacities are now ready to start up and just slowly get introduced into the market. As soon as this supply-demand balance is more balanced, we will see most probably other price levels. It's a little bit hard to forecast when this exactly will happen. We, on our side, do not have the crystal ball for that.
I think we can only give you our assessment here. Q2 looks good, and for the second half, we have to see how the global market balances out in the end. On the specific shape of our methacrylates business, I think it's a little bit too early to give you very much in detail, how it will look in the end. The biggest part is our MMA and PMMA business, representing EUR 1.5 billion in sales in last year. We have there around this, on the side, some smaller businesses that are part of the same production chain, or where it really makes sense from a product portfolio point of view to group them to this entity. We are just now looking into that. It's also a question of internal, a supply contract, delivery contract.
There we need some work to do, but I think the maximum additional sales is something like EUR 150 million, EUR 200 million. It does not really move the needle too much. Our thinking was more to really present, from the industry point of view, a logical production portfolio and a good product portfolio, which really makes sense then for the new owner.
Thanks.
Our final question is from Geoff Haire of UBS. Please proceed.
Thank you very much. Two questions, both in Nutrition & Care. Looking at Nutrition & Care, you had no sales growth, at least on the reported number, but yet EBITDA was up 12%. Clearly, assuming there was good performance in some of your higher margin businesses, just wonder if you could comment on what is driving that EBITDA growth with no sales growth and also how sustainable that is. Then secondly, I think, Ute, you made a comment that the dissolution of the SAP JV with Daicel has given you a EUR 50 million uplift for the full year. I may be wrong on this, but my memory was that it was a lower number than that. It was around about EUR 10. I just wonder if you could comment on what is driving that EUR 50 million uplift.
Yeah. Okay. On the sales line, I want to reemphasize that the currency impact on Nutrition & Care is stronger than on the whole group. Maybe that partially explains or answers your question as well. If we look at the overall segment, we are pleased to see a good earnings growth and also margin progression. This is not only driven by methionine, a little bit. We have seen higher earnings in personal care, Comfort & Insulation, and healthcare. We have increased our prices successfully in Comfort & Insulation. Healthcare had a strong quarter. With healthcare, they have a very own seasonal pattern. Some quarters are very strong, some are weaker. This is a very good start into the year. We can have some fluctuations between the quarters, but overall, they have a very good pipeline.
They acquired a lot of projects in the last years, which really now start up and get ramped up. I think that will also support the growth and the earnings for the full year in healthcare. In personal care, we have a strong business. We also are managing our product portfolio here in a more specialty way so that we have better margins, maybe not so much better sales. That could partially explain your observation. Also the Dr. Straetmans acquisition helps a lot here. We have the cost savings in Animal Nutrition from our Adjust 2020 program and also from the dissolution of the Baby Care joint venture. I do not exactly know what you refer to, but I think we always said some EUR 10 million to EUR 15 million. We are now a little bit towards the upper end of this range.
From our point of view, we are now in a situation that methionine is on a more normalized level. The good development of the other business becomes now visible and more relevant drivers for the performance of the segment.
Ladies and gentlemen, this concludes today's question and answer session. At this time, I would like to turn the conference back to you for any additional or closing remarks.
Thank you very much. Ladies and gentlemen, before we come to the end of today's call, I would like to reiterate our invitation to our Capital Markets Day. It will take place in Essen on September 13 and 14. Further details and the invitation will follow shortly. I'm looking very much forward to seeing you there or before at our road shows in Frankfurt, London, Milan, Paris and Zurich in the next weeks. Thank you for your attention today, and goodbye.
Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.